Holen Sie sich die Stockscreener-App
0.85
0.15%
0.0013
Handel nachbörslich:
.85
Schlusskurs vom Vortag:
$0.8487
Offen:
$0.8969
24-Stunden-Volumen:
6,298
Relative Volume:
0.16
Marktkapitalisierung:
$17.47M
Einnahmen:
$31.56M
Nettoeinkommen (Verlust:
$-46.89M
KGV:
-0.2803
EPS:
-3.0329
Netto-Cashflow:
$-26.70M
1W Leistung:
+11.84%
1M Leistung:
-11.47%
6M Leistung:
-34.62%
1J Leistung:
-72.40%
1-Tages-Spanne:
$0.8358
$0.8969
1-Wochen-Bereich:
$0.75
$0.9144
52-Wochen-Spanne:
$0.75
$3.29
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Firmenname
Casi Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CASI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
0.85 | 17.44M | 31.56M | -46.89M | -26.70M | -3.0329 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Eingeleitet | Mizuho | Buy |
| 2020-10-23 | Eingeleitet | Oppenheimer | Outperform |
| 2016-09-22 | Eingeleitet | Maxim Group | Buy |
| 2015-10-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Casi Pharmaceuticals Inc Aktie (CASI) Neueste Nachrichten
CASI Pharmaceuticals Closes First US$5 Million Tranche of Convertible Note Financing - TipRanks
CASI Pharmaceuticals (NASDAQ: CASI) issues US$5M 12% convertible note as first tranche - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension By Investing.com - Investing.com India
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026 By Investing.com - Investing.com Nigeria
CASI Pharmaceuticals Wins Nasdaq Listing Extension to February 2026 - TipRanks
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements - Investing News Network
CASI Pharmaceuticals wins Nasdaq extension to meet listing rules - MSN
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension - Investing.com
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026 - Investing.com
CASI Pharmaceuticals gets extra time to stay on Nasdaq - Stock Titan
How CASI Pharmaceuticals Inc. stock trades during market volatility2025 Year in Review & Safe Capital Growth Plans - Улправда
Published on: 2025-12-21 10:42:27 - Улправда
What margin trends mean for CASI Pharmaceuticals Inc. stockTake Profit & Smart Swing Trading Techniques - Улправда
Is CASI Pharmaceuticals Inc. stock a safe buy before earnings2025 Price Momentum & AI Powered Market Trend Analysis - bolumsonucanavari.com
Will CASI Pharmaceuticals Inc. stock benefit from infrastructure spendingEarnings Overview Report & Daily Market Momentum Tracking - DonanımHaber
Will CASI Pharmaceuticals Inc. stock benefit from AI adoptionTrade Analysis Report & AI Driven Price Predictions - DonanımHaber
What valuation multiples suggest for CASI Pharmaceuticals Inc. stock2025 Market WrapUp & Reliable Breakout Forecasts - DonanımHaber
Why CASI Pharmaceuticals Inc. stock could rally in 20252025 Market WrapUp & Safe Entry Trade Reports - DonanımHaber
Fed Watch: What analyst consensus says on CASI Pharmaceuticals Inc. stockRate Hike & Reliable Breakout Forecasts - Улправда
Aug PreEarnings: Is CASI Pharmaceuticals Inc stock a contrarian buyJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - moha.gov.vn
CASI Pharmaceuticals, Inc. announced that it expects to receive $20 million in funding from Emerging Technology Partners, LLC - marketscreener.com
CASI Pharmaceuticals secures $20 million funding for transplant rejection study - Investing.com
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing - Investing News Network
CASI Pharmaceuticals Secures $20 Million for Renal AMR Study - TipRanks
CASI Pharmaceuticals secures $20 million funding for transplant rejection study By Investing.com - Investing.com South Africa
CASI Pharmaceuticals (NASDAQ: CASI) plans $20 million notes to fund China AMR trial - Stock Titan
CASI Pharmaceuticals reports positive phase 1 data for ITP treatment - Investing.com
CASI Pharmaceuticals reports positive phase 1 data for ITP treatment By Investing.com - Investing.com Australia
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting - ACCESS Newswire
Casi Pharmaceuticals announces CID-103 immune thrombocytopenia study results - MSN
How sustainable is CASI Pharmaceuticals Inc. stock dividend payoutEarnings Trend Report & Verified Technical Trade Signals - Newser
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES - GuruFocus
CASI Pharmaceuticals, Inc. (CASI) 6.93% in After-hours: What’s Driving the Move? - Stocks Telegraph
Hedge Fund Moves: What margin trends mean for CASI Pharmaceuticals Inc. stockWeekly Profit Analysis & Weekly Watchlist for Hot Stocks - moha.gov.vn
CASI Pharmaceuticals Announces Changes in Board Governance - Investing News Network
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - Investing News Network
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ - Investing News Network
Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop - simplywall.st
CASI Pharmaceuticals Inc. (CASI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Casi Pharmaceuticals appoints James Huang as non-executive chairman - MSN
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman - The Globe and Mail
How resilient is CASI Pharmaceuticals Inc. stock in market downturns2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com
How CASI Pharmaceuticals Inc. stock performs in weak economyGap Up & Daily Growth Stock Tips - newser.com
How to read the order book for CASI Pharmaceuticals Inc.2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Is CASI Pharmaceuticals Inc. stock gaining market shareJuly 2025 Trends & Growth Oriented Trade Recommendations - newser.com
Is CASI Pharmaceuticals Inc. stock a top momentum playMarket Performance Summary & Weekly High Potential Alerts - newser.com
[6-K] CASI Pharmaceuticals, Inc. Current Report (Foreign Issuer) | CASI SEC FilingForm 6-K - Stock Titan
CASI Pharmaceuticals (NASDAQ: CASI) appoints James Huang Non-Executive Chairman - Stock Titan
Finanzdaten der Casi Pharmaceuticals Inc-Aktie (CASI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):